Alembic Straddles Oversupply And Shortages In US

One-off opportunities lift Alembic’s US generics business in the fiscal second quarter but the market continues to pose challenges amid surging oversupply and price erosion. On the other hand, a string of injectable approvals, including for ketorolac tromethamine, could open up opportunities for the company given the 'on and off' shortages.

US Generics Market Sees Signficant Oversupply • Source: Shutterstock

Alembic Pharmaceuticals rang in robust growth in the US in the fiscal second quarter, albeit on a smaller base compared with some peers but the firm’s management signaled heightened pressure in that market amid a huge supply glut. On the flip side, product shortages in the US are seen fueling gains for the Indian company.

More from Earnings

More from Business